Krka Does Not Expect Short-Term Damage Due to Changes in Act on Medicinal Products
Novo Mesto, 22 January - Revenues of the Slovene pharmaceutical company Krka topped SIT 72 billion (EUR 324 million) in 2001, exceeding those of 2000 by 17 percent. Net profits, too, recorded a substantial increase year-on-year, Krka chief executive Milos Kovacic told the press on Tuesday, however he refused to disclose the exact figure before the management board convenes in February.
The rest of this news item is available to subscribers.
The news item consists of 2.265 characters (without spaces) or 431 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.